---

Migraines: Drugs

Answer

The Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency of the Department with responsibility for ensuring medicines meet appropriate standards of quality, efficacy, and safety.

The MHRA has plans to gather the currently available evidence on mental health and other related risks for licensed migraine prophylaxis medications, as referenced in the separate responses to questions HL1488 and HL1543. A formal timeline for this review has not yet been agreed, and consequently we are unable to provide an expected completion date at this stage.

The MHRA is committed to communicating any findings that may have implications for patient safety or the safe use of medicines. The MHRA will sometimes issue communications, such as drug safety updates, after the conclusion of a review. However, the review is at an early stage, and it would be premature to comment on any potential communication plans. In addition, any product information changes that may arise as a result of this review would be reflected in the published product information available at locations such as the MHRA website or the Electronic Medicines Compendium website.

Secondary information

Type

Written question

Reference

HL1995

Session

2026-27

Related items

Migraines: Drugs
Monday, 6 July 2026
Written questions
House of Lords

Grouped for answer

Yes

Subjects

Drugs Mental health Medicines and Healthcare products Regulatory Agency Side effects Migraines

Link

View this Written question on www.parliament.uk